Under the title of “Endeavoring New Possibilities”, Sandoz Egypt has announced a specialized program for the exchange of scientific expertise among thought leaders from Egypt and the world in the organ transplantation field. The program aims to discuss the latest developments in kidney and liver transplants, based on sound scientific foundations for medical practice. It will review the latest updates tackled at kidney and liver transplantation conferences around the world and evaluate different countries’ experiences in using generic immunosuppressants to help optimize organ transplantation operations. The program is scheduled to be held online over a three-month period between October and December 2020, with the participation of specialists from Egypt and international experts from European and Asian countries.
“The continuous developments in organ transplantations and intensive research carried out in this vital medical domain have made it a necessity to keep up with the latest scientific updates in the field that are in line with sound medical practices. Organ transplantation is a priority for Sandoz and we are therefore committed to taking the initiative to innovate and develop high-quality treatments in this area, cooperating with local entities whenever possible to contribute to the medical field in Egypt and make necessary treatments available to the largest number of patients,” said Dr. Sameh El Bagoury, Country Head for Sandoz Egypt and Libya. He also praised the remarkable progress Egypt has made in kidney and liver transplants over the past few years, saving the lives of many patients in the country.
Prof. Hany Hafez, Nephrology professor at Cairo University and President of the Egyptian Society of Nephrology and Transplantation, said that the scientific program would focus on the challenges faced by the kidney transplant program and the tools and measures available to prevent or slow down kidney function deterioration several years after surgery. He noted that two of the main reasons for unsuccessful operations in the long term are graft rejection and viral infections. The program will also address the possibility of tailoring a protocol of immunosuppressant drugs to each individual transplant patient and will review the latest updates discussed at kidney transplant conferences in 2020. The program will probe ways to cut the costs covered by the state and patients, showcasing other countries’ experiences in using generic immunosuppressants.
Ain Shams University hepatobiliary surgery professor, President of the Middle East Society for Organ Transplantation, elected council member of the living donor liver transplantation study group and liver transplant pioneer in Egypt, Prof. Refaat Kamel, said that the scientific program would include a group of international experts in the liver transplant field which represents a true opportunity for the exchange of scientific expertise, allowing local physicians and consultants to benefit from other countries’ experiences. “The work of Egyptian doctors specialized in liver transplants is on a par with the progress the world has achieved in the field and they have distinguished expertise in this area,” he said.
“Cooperation in scientific activities between Sandoz and the national medical community is a cornerstone of our commitment to Egypt and a crucial element of continuous medical education, which we view as essential. Updating available information and spreading awareness about the latest research results in the kidney and liver transplant fields can improve the level of medical services provided to Egyptian patients, from diagnosis to treatment and follow-up,” said Dr. Peter Effat, the Head of the medical sector at Sandoz Egypt.
“Sandoz earlier this year announced the launch of two new immunosuppressants that have demonstrated their capacity to boost the success rates of kidney and liver transplant operations and improve the health conditions of patients. The two drugs, Tacrolimus (0.5 gm and 1 gm) and Mycophenolate Mofetil (500 mg), were produced in line with strict Sandoz standards and have obtained the approval of the US Food and Drug Authority (FDA). Both have effectively reduced transplanted organ rejection rates and have helped patients achieve a better quality of life,” added Dr. Peter Effat.
© 2020 Daily News Egypt. Provided by SyndiGate Media Inc. (Syndigate.info).
